ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Atara Biotherapeutics, Inc.

611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
650-278-8930
http://www.atarabio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees321

Key Executives

NameTitlePayExercisedYear Born
Dr. Isaac E. CiechanoverPres, CEO & Director1.05MN/A1971
Mr. Utpal KoppikarChief Financial Officer430.46kN/A1970
Mr. Joseph NewellExec. VP & Chief Technical Operations Officer536.58k292.72k1970
Ms. Mina KimSr. VP of Corp. Strategy, Gen. Counsel & Sec.457.91kN/A1974
Dr. Dietmar P. Berger M.D., Ph.D.Global Head of R&D748.6kN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Corporate Governance

Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.